Skip to content
Peptigraph home

Mazdutide Phase 3 trial (NCT05607680)

A Randomized, Double-blind, Placebo-controlled Phase III Study Evaluating the Efficacy and Safety of IBI362 in Chinese Participants With Obesity or Overweight (GLORY-1)

Registry record checked

At a glance

Phase
Phase 3
Status
Completed
Enrolment
610
actual
Start
14 Nov 2022 (actual)
Primary completion
21 Aug 2023 (actual)
Sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Design

Arms and doses

NCT05607680 study arms
ArmTypeInterventionsDescription
PlaceboPlacebo comparatorDrug: PlaceboPlacebo,SC,once a week for 48 weeks
IBI362 4 mgExperimentalDrug: IBI3622 mg,SC,once a week for 4 weeks 4 mg,SC,once a week for 44 weeks
IBI362 6 mgExperimentalDrug: IBI3622 mg,SC,once a week for 4 weeks 4 mg,SC,once a week for 4 weeks 6 mg,SC,once a week for 40 weeks
Endpoints

Primary endpoint

NCT05607680 primary outcomes
MeasureTime frame
Percent Change from Baseline in Body WeightBaseline, Week 32
Percentage of Participants who Achieve ≥5% Body Weight ReductionWeek 32
Endpoints

Key secondary endpoints

The first secondary outcomes listed on the registry record.

NCT05607680 secondary outcomes
MeasureTime frame
Percentage of Participants who Achieve ≥10%Body Weight ReductionWeek 32,Week 48
Percentage of Participants who Achieve ≥15% Body Weight ReductionWeek 32,Week 48
Change from Baseline in Waist CircumferenceBaseline, Week 32,Week 48
Percent Change from Baseline in Body WeightBaseline, Week 48
Percentage of Participants who Achieve ≥5% Body Weight ReductionWeek 48
Percentage of Participants who Achieve ≥20% Body Weight ReductionWeek 32, Week 48
Change from Baseline in Neck CircumferenceBaseline, Week 32, Week 48
Change from Baseline in Hip CircumferenceBaseline, Week 32, Week 48
Change from Baseline in Body WeightBaseline, Week 32, Week 48
Percent Change from Baseline in Body WeightBaseline, Week 60
Change from Baseline in Body Mass Index (BMI)Baseline, Week 32, Week 48
Percentage of Participants with BMI < 24 kg/m2Week 32, Week 48
Eligibility

Who could enrol

Sex
All
Minimum age
18 Years
Maximum age
Not stated
Results

Results

No results posted on ClinicalTrials.gov as of 2 Oct 2026.

GLORY-1 results as published for 4 mg and 6 mg mazdutide

Chinese adults with a BMI of at least 28, or 24 to under 28 with a weight-related condition, were randomised 1:1:1 to mazdutide 4 mg, 6 mg or placebo for 48 weeks.[2]

At week 32 weight changed by -10.09% on 4 mg, -12.55% on 6 mg and +0.45% on placebo, and 73.9%, 82.0% and 10.5% respectively lost at least 5%.[2]

At week 48 the weight changes were -11.00%, -14.01% and +0.30%, with 35.7%, 49.5% and 2.0% losing at least 15%.[2]

Adverse events led to discontinuation in 1.5% on 4 mg, 0.5% on 6 mg and 1.0% on placebo.[2]

Sources

  1. 1A Randomized, Double-blind, Placebo-controlled Phase III Study Evaluating the Efficacy and Safety of IBI362 in Chinese Participants With Obesity or Overweight (GLORY-1)ClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026
  2. 2Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight.The New England journal of medicine · 2025PMID 40421736Accessed 2 Oct 2026

Found an error? Report a correction.